Role of human albumin in the management of complications of liver cirrhosis

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue 4, 2014, Pages 302-311

  Bernardi, Mauro ^a   Ricci, Carmen S ^a   Zaccherini, Giacomo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Albumin; Ascites; Bacterial infections; Cirrhosis of the liver; Non oncotic properties of albumin

Indexed keywords

ANTIBIOTIC AGENT; DIURETIC AGENT; HUMAN ALBUMIN; LACTITOL; LACTULOSE; METAL; RIFAXIMIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ANTIOXIDANT ACTIVITY; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BINDING AFFINITY; BODY FLUID; DISEASE SEVERITY; DRUG ACTIVITY; DRUG COST; DRUG INDICATION; EVIDENCE BASED PRACTICE; EXTRACELLULAR FLUID; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HOSPITAL PATIENT; HUMAN; HYPOVOLEMIA; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; METAL BINDING; ONCOTIC PRESSURE; PARACENTESIS; PATHOPHYSIOLOGY; PROTEIN DOMAIN; PROTEIN SYNTHESIS; REVIEW; SCAVENGING ACTIVITY; SURFACE CHARGE; VASODILATATION;

EID: 84920730839     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.08.007     Document Type: Review

References (48)

1. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358:209-215.
2. Carter D.C., He X.M., Munson S.H., et al. Three-dimensional structure of human serum albumin. Science 1989, 244:1195-1198.
3. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990, 37:57-84.
4. Quinlan G.J., Martin G.S., Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology 2005, 41:1211-1219.
5. Chen W., Gassner B., Börner S., et al. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res 2012, 93:141-151.
6. Henricksen J.H., Siemssen O., Krintel J.J., Malchow-Møller A., Bendtsen F., Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. JHepatol 2001, 34:53-60.
7. Garcia-Martinez R., Caraceni P., Bernardi M., Gines P., Arroyo V., Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013, 58:1836-1846.
8. Oettl K., Stauber R.E. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007, 151:580-590.
9. Bruschi M., Candiano G., Santucci L., Ghiggeri G.M. Oxidized albumin. The long way of a protein of uncertain function. Biochim Biophys Acta 2013, 1830:5473-5479.
10. Bernardi M., Predieri S. Disturbances of acid-base balance in cirrhosis: a neglected issue warranting further insights. Liver Int 2005, 2:463-466.
11. Oettl K., Stadlbauer V., Petter F., et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008, 1782:469-473.
12. Jalan R., Schnurr K., Mookerjee R.P., et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009, 50:555-564.
13. Domenicali M., Baldassarre M., Giannone F.A., et al. Post-transcriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 2014, 10.1002/hep.27322.
14. Giannone F.A., Domenicali M., Baldassarre M., et al. Ischemia modified albumin (IMA) as a novel diagnostic marker of bacterial infection in hospitalized patients with cirrhosis. Abstract, The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013.
15. Henriksen J.H., Stage J.G., Schlichting P., Winkler K. Intraperitoneal pressure: ascitic fluid and splanchnic vascular pressures, and their role in prevention and formation of ascites. Scand J Clin Lab Invest 1980, 40:493-501.
16. Arroyo V., Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011, 10:S6-S14.
17. Bernardi M., Maggioli C., Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care 2012, 16:211.
18. Ruiz-del-Arbol L., Monescillo A., Jimenéz W., Garcia-Plaza A., Arroyo V., Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997, 113:579-586.
19. Ginès A., Fernández-Esparrach G., Monescillo A., et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996, 111:1002-1010.
20. Ginès P., Titó L., Arroyo V., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94:1493-1502.
21. Sola-Vera J., Mi-ana J., Ricart E., et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003, 37:1147-1153.
22. Moreau R., Valla D.-C., Durand-Zaleski I., et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver Int 2006, 26:46-54.
23. Bernardi M., Caraceni P., Navickis R.J., Wilkes M.M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012, 55:1172-1181.
24. Rimola A., García-Tsao G., Navasa M., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. JHepatol 2000, 32:142-153.
25. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. JHepatol 2010, 53:397-417.
26. Fernández J., Gustot T. Management of bacterial infections in cirrhosis. JHepatol 2012, 56:S1-S12.
27. Salerno F., Gerbes A., Ginès P., Wong F., Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007, 56:1310-1318.
28. Salerno F., Monti V. Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis. Hepatology 2014, 59:1239-1241.
29. Gluud L.L., Christensen K., Christensen E., Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010, 51:576-584.
30. Martín-Llahí M., Pépin M.N., Guevara M., et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359.
31. Sanyal A.J., Boyer T., Garcia-Tsao G., et al. Arandomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008, 134:1360-1368.
32. Ortega R., Ginès P., Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002, 36:941-948.
33. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005, 129:1944-1953.
34. Fasolato S., Angeli P., Dallagnese L., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007, 45:223-229.
35. Guevara M., Terra C., Nazar A., et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. JHepatol 2012, 57:759-765.
36. Khungar V., Poordad F. Hepatic encephalopathy. Clin Liver Dis 2012, 16:301-320.
37. Bajaj J.S., Wade J.B., Gibson D.P., et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011, 106:1646-1653.
38. García-Martínez R., Córdoba J. Acute-on-chronic liver failure: the brain. Curr Opin Crit Care 2011, 17:177-183.
39. Als-Nielsen B., Gluud L., Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004, CD003044.
40. Bass N., Mullen K. Rifaximin treatment in hepatic encephalopathy. NEng J Med 2010, 362:1071-1081.
41. Jalan R., Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci 2004, 106:467-474.
42. Simón-Talero M., García-Martínez R., Torrens M., et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. JHepatol 2013, 59:1184-1192.
43. Gentilini P., Casini-Raggi V., Di Fiore G., et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. JHepatol 1999, 30:639-645.
44. Romanelli R.G., La Villa G., Barletta G., et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12:1403-1407.
45. Bortoluzzi A., Ceolotto G., Gola E., et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 2013, 57:266-276.
46. Bañares R., Nevens F., Larsen F.S., et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013, 57:1153-1162.
47. Dethloff T., Tofteng F., Frederiksen H.J., Hojskov M., Hansen B.A., Larsen F.S. Effect of prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study. World J Gastroenterol 2008, 14:2065-2071.
48. Mirici-Cappa F., Caraceni P., Domenicali M., et al. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol 2011, 17:3479-3486.